Monica Kraft
Pulmonary Disease · New York, NYNPI 1023192937
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $188,022 of the $246,543 with a category attached, or 76.3%. 15 manufacturers reported payments, led by GSK at 27.3% of the total. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $1786.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$67K
- Sanofi$56K
- Chiesi USA, Inc.$30K
- AstraZeneca$27K
- Regeneron Healthcare Solutions, Inc.$12K
- Regeneron$11K
- plus $44K from 9 others
Across 82 payments — averaging $2767.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$123K
- AstraZeneca$48K
- Janssen Research & Development, LLC$39K
- F. Hoffmann-la Roche AG$7K
- Astrazeneca AB$6K
- Sanofi$3K
- plus $2K from 2 others
What the payments were for
- Consulting fees$188,02276%
- Speaking & faculty fees$37,80215%
- Travel & lodging$17,7987%
- Food & beverage$2,9211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 26 | $67,220 |
| Sanofi | 17 | $56,135 |
| Chiesi USA, Inc. | 14 | $29,523 |
| AstraZeneca | 30 | $26,536 |
| Regeneron Healthcare Solutions, Inc. | 8 | $11,819 |
| Regeneron | 10 | $11,332 |
| Boehringer Ingelheim | 3 | $9,360 |
| Sanofi-aventis U.S. LLC | 7 | $8,372 |
| Genentech USA, Inc. | 8 | $8,189 |
| Merck | 8 | $5,386 |
| Novartis | 2 | $3,834 |
| Genentech, Inc. | 2 | $2,816 |
| Pfizer | 1 | $2,500 |
| Astrazeneca UK Limited | 1 | $2,250 |
| F. Hoffmann-la Roche AG | 1 | $1,272 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$55,231
- TRELEGY ELLIPTA$8,125
- XOLAIR$6,634
- NUCALA$6,344
- STIOLTO RESPIMAT$6,240
- FASENRA$2,629
- AIRSUPRA$1,746
- Non-Covered Product$1,272
How this compares
$246,543 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
- Kenneth BergerNew York$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.